Axial Spondyloarthritis Drugs Market Size, Share, Analysis, Industry Report and Forecast 2021-2027
The global axial spondyloarthritis drugs market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Axial spondyloarthritis is a type of inflammatory arthritis. It primarily affects the spine and the sacroiliac (SI) joints that are connected to the lower spine to the pelvis which results in pain in the lower back, hips, and buttocks. The major factor driving the growth of the market is the new product launches and drug approval across the globe.
For instance, in August 2019, Eli
Lilly and Company announced the approval of Taltz (ixekizumab) injection 80
mg/mL from the US Food and Drug Administration (FDA). It is used for the
treatment of active ankylosing spondylitis (AS) which is also known as
radiographic axial spondyloarthritis (r-axSpA) in adults. Additionally, in June
2020, Novartis announced the approval of Cosentyx (secukinumab) from the US
Food and Drug Administration (FDA). It is used for the treatment of active
non-radiographic axial spondyloarthritis (nr-axSpA).
To Request a Sample of our Report on Axial
Spondyloarthritis Drugs Market: https://www.omrglobal.com/request-sample/axial-spondyloarthritis-drugs-market
Some major players in the market include AbbVie Inc.,
Novartis International AG, and Johnson & Johnson, among others. The market
players are contributing significantly to the growth of the market by the
adoption of various strategies including mergers & acquisitions,
geographical expansion, partnerships and collaborations, and new product
launches, to stay competitive in the market. For instance, in January 2022,
AbbVie announced the submission of applications to seek approvals for
upadacitinib (RINVOQ, 15 mg) to the U.S. Food and Drug Administration (FDA) and
the European Medicines Agency (EMA). Upadacitinib (RINVOQ, 15 mg) is used
for the treatment of active non-radiographic axial spondyloarthritis (nr-axSpA)
with objective signs of inflammation in adults who have responded inadequately
to nonsteroidal anti-inflammatory drugs (NSAIDs).
Market Coverage
• The
market number available for – 2020-2027
• Base
year- 2020
• Forecast
period- 2021-2027
Segment Covered-
•
By Type
•
By Application
Regions Covered-
•
North America
•
Europe
•
Asia-Pacific
•
Rest of the World
Competitive Landscape- AbbVie Inc., Novartis
International AG, and Johnson & Johnson Services, Inc., among others.
(Get 15% Discount on Buying this Report)
A
full Report of Axial Spondyloarthritis Drugs Market is Available @ https://www.omrglobal.com/industry-reports/axial-spondyloarthritis-drugs-market
Global Axial Spondyloarthritis Drugs Market Report by
Segment
By Type
• Certolizumab
Pegol
• Etanercept
Biosimilar
• Ixekizumab
• Secukinumab
• Others
By Application
• Clinic
• Hospital
• Homecare
Global Axial Spondyloarthritis Drugs Market Report by
Region
North America
·
United States
·
Canada
Europe
·
UK
·
Germany
·
Spain
·
France
·
Italy
·
Rest of Europe
Asia-Pacific
·
India
·
China
·
Japan
·
South Korea
·
Rest of APAC
Rest of the World
·
Latin America
·
Middle East & Africa
Reasons to buy from us –
1. We cover more than
15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries
are for analysis.
3. Over 100+ paid
data sources mined for investigation.
4. Our expert
research analysts answer all your questions before and after purchasing your
report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company
known for its crisp and concise reports. The company is equipped with an
experienced team of analysts and consultants. OMR offers quality syndicated
research reports, customized research reports, consulting and other
research-based services.
Media
Contact:
Company
Name: Orion Market Research
Contact
Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact
no: +91 7803040404
Comments
Post a Comment